Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Phase I
Biotech
Vor Bio's dual stem cell, ADC shows consistent engraftment
Vor Bio plans to accelerate enrollment of a phase 1/2 trial of its dual stem cell-ADC cancer therapy to get a fuller picture of post-relapse response.
Max Bayer
Nov 9, 2023 4:10pm
Mediar gets a spark from Pfizer's Ignite program
Oct 25, 2023 10:50am
Alaunos winds down sole cell therapy trial, cuts 60% of staff
Aug 15, 2023 10:53am
Beam aims to dose first patient in sickle cell trial this year
Aug 8, 2023 4:10pm
Precision on the partnership prowl for lead asset after FDA chat
Jul 27, 2023 10:57am
Viridian looks to beat Horizon's Tepezza in thyroid eye disease
Jul 10, 2023 4:01pm